Chiome Bioscience Inc 4583
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- JPY 123.00
- Day Range
- JPY 121.00–125.00
- 52-Week Range
- JPY 117.00–234.00
- Bid/Ask
- JPY 123.00 / JPY 125.00
- Market Cap
- JPY 6.76 Bil
- Volume/Avg
- 340,100 / 697,178
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 68
- Website
- http://www.chiome.co.jp
Comparables
Valuation
|
Metric
|
4583
|
4893
|
4565
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 30.10 |
Price/Book Value | 5.77 | 1.32 | 1.95 |
Price/Sales | 9.22 | 22.64 | 9.42 |
Price/Cash Flow | — | — | — |
Price/Earnings
4583
4893
4565
Financial Strength
|
Metric
|
4583
|
4893
|
4565
|
|---|---|---|---|
Quick Ratio | 2.66 | 65.18 | 3.29 |
Current Ratio | 3.02 | 66.28 | 3.79 |
Interest Coverage | −586.25 | — | −3.82 |
Quick Ratio
4583
4893
4565
Profitability
|
Metric
|
4583
|
4893
|
4565
|
|---|---|---|---|
Return on Assets (Normalized) | −64.12% | −19.85% | −4.62% |
Return on Equity (Normalized) | −88.64% | −20.61% | −9.26% |
Return on Invested Capital (Normalized) | −73.62% | −20.61% | −4.48% |
Return on Assets
4583
4893
4565
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mwljttgrhk | Qmb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gqhtvrkv | Tbxkgd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hcxyvqwpg | Pcsqvqh | $97.8 Bil | |
MRNA
| Moderna Inc | Vtrrgqy | Prvlz | $41.3 Bil | |
ARGX
| argenx SE ADR | Hcjstcgb | Xtks | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rpcqcqcr | Jjsh | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rywjtzsf | Jtrpcrh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xtqbdxly | Jyhthhf | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mfrycnhkp | Tnjzd | $12.5 Bil | |
INCY
| Incyte Corp | Vbzlmfp | Ldlkz | $11.6 Bil |